This site contains forward-looking statements that are based on the management’s current expectations and beliefs regarding future events, and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described. You should not place undue reliance on these statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited estimates of revenues, capital expenditures, cash, other financial metrics, expected legal, regulatory, or clinical results, and other such estimates and results.

Unless otherwise noted, Axentis Pharma AG is providing this information as of March 22, 2010 and expressly disclaims any obligation to update information contained in this presentation. Forward-looking statements involve significant risk factors related to our business and uncertainties, including but not limited those discussed below.

Axentis Pharma AG’s results may be affected by our ability to successfully develop, partner and market our products domestically and internationally, difficulties or delays in manufacturing our products, and regulatory developments involving current and future products and manufacturing facilities. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated, or circumvented by our competitors. Our business may be impacted by government investigations, litigation, and products liability claims.

The information posted on this site does not constitute a recommendation, offer, or solicitation to sell or to buy Axentis Pharma AG’s securities.